BUSINESS

Aura, Cabaletta Complete Major Public Offerings This Week

▪

Read, Watch or Listen

Media Bias Meter

Sources: 4

Center 100%

Sources: 4

Boston — Aura Biosciences announced on May 4 that it priced an underwritten public offering of common stock and pre-funded warrants, offering 39,591,000 shares and up to 3,800,000 pre-funded warrants at $6.00 and $5.99999 respectively; the company granted underwriters a 30-day option for additional shares. Boston and Philadelphia reports this week show related financing activity in the biotech sector: Aura reported the offering closed on May 5 with full exercise of the underwriters’ option, generating approximately $299.4 million in gross proceeds, while Cabaletta priced an at-the-market offering on May 4 expected to raise about $150 million with institutional participation, including Eli Lilly.

Prepared by Christopher Adams and reviewed by editorial team.

Timeline of Events

May 4, 2026 — Aura announced launch of an underwritten public offering via GlobeNewswire.
May 4, 2026 — Cabaletta Bio priced an at-the-market offering expected to raise about $150 million.
May 4, 2026 — Aura priced 39,591,000 shares and up to 3,800,000 pre-funded warrants at $6.00/$5.99999.
May 5, 2026 — Aura closed the offering, with underwriters fully exercising the option; gross proceeds about $299.4 million.
May 5–6, 2026 — News outlets published the pricing and closing notices, listing underwriters and participating investors.

Why This Matters to You

These public offerings by Aura and Cabaletta are big moves in the biotech sector. They show investor confidence, which can influence the stock market. If you're invested in biotech or considering it, keep an eye on these companies.

The Bottom Line

Aura and Cabaletta's successful offerings raised significant funds, signaling a robust biotech market. It's a good reminder to review your investment strategy. Worth forwarding if you know someone interested in biotech stocks.